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The CX3CR1 (chemokine (C-X3-C motif) receptor 1) expression levels on immune cells have 35 
significant importance in maintaining tissue homeostasis under physiological and pathological 36 
conditions. The factors implicated in the regulation of CX3CR1 and its specific ligand 37 
CX3CL1 (fractalkine) expression remain largely unknown. Recent studies provide evidence 38 
that host`s misfolded proteins occurring in the forms of polymers or amyloid fibrils can 39 
regulate CX3CR1 expression. Herein, a novel example demonstrates that polymers of human 40 
ZZ alpha-1 antitrypsin (Z-AAT) protein, resulting from its conformational misfolding due to 41 
the Z (Glu342Lys) mutation in SERPINA1 gene, strongly lower CX3CR1 mRNA expression 42 
in human PBMCs. This parallels with increase of intracellular levels of CX3CR1 and Z-AAT 43 
proteins. Presented data indicate the involvement of the CX3CR1 pathway in the Z-AAT-44 
related disorders and further support the role of misfolded proteins in CX3CR1 regulation. 45 
Key words:  46 
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Introduction 48 
Interactions between the chemokine receptors and chemokines, but also other proteins, 49 
peptides, lipids, and microbial products, play a critical role in the recruitment of inflammatory 50 
cells into injured/diseased tissues
1
. Many human diseases involve altered surface expression 51 
of chemokine receptors, which can lead to a defective cell migration and inappropriate 52 
immune response. Most of the human PBMCs express CX3CR1
2
, also known as the G-53 
protein coupled receptor 13 (GPR13) or fractalkine receptor, a mediator of leukocyte 54 
migration and adhesion. In the central nervous system, CX3CR1 is largely expressed by 55 
microglial cells (brain macrophages)
3, which are involved in neurodegenerative diseases like 56 
Alzheimer’s disease. The major role of CX3CR1-expressing cells is to recognize and enter 57 
tissue following CX3CL1 (fractalkine or also called neurotactin) gradient, and to crawl or 58 
“patrol” in the lumen of blood vessels
4
. Since CX3CR1/CX3CL1 axis is also involved in the 59 
synthesis of anti-inflammatory cytokines and has a significant role in cytoskeletal 60 
rearrangement, migration, apoptosis and proliferation, its dysregulation is associated with the 61 
development of cardiovascular diseases, kidney ischemia–reperfusion injury, cancer, chronic 62 
obstructive pulmonary disease (COPD), neurodegenerative disorders and others
5-7
. Some 63 
studies indicate that CX3CR1 deficiency contributes to the severity of infectious diseases
8
, 64 
and promotes lung pathology in respiratory syncytial virus-infected mice
9
. Animals with 65 
deletion of CX3CR1 show impaired  phagocytosis
10
, which is a vital to prevent unwanted 66 
inflammation. It is clear that CX3CR1 expressing cells have tissue-specific roles in different 67 
pathophysiological conditions. Nevertheless, a comprehensive knowledge on the regulation of 68 
CX3CR1 expression is still missing.  69 
Current findings suggest that divergent proteins with a common propensity to form 70 
extracellular oligomers interact with chemokine receptors and affect their expression levels. 71 
For example, Alzheimer`s peptide, Aβ, interacts with CX3CR1 and significantly reduces its 72 
expression in cultured microglial cells and in Alzheimer`s brain
11
. Similarly, highly 73 
aggregated extracellular Tau protein binds to CX3CR1, promotes its internalization and 74 
reduces expression in microglial cells
12
. In concordance, polymers of human Z alpha-1 75 
antitrypsin (Z-AAT), resulting from protein misfolding due to the Z (Glu342Lys) mutation in 76 
SERPINA1 gene,  lower CX3CR1 mRNA in human PBMCs, which parallels with increased 77 
intracellular CX3CR1 and Z-AAT protein levels.  78 
Results and Discussion 79 
Inherited alpha-1 antitrypsin deficiency (AATD) is a rare genetic condition caused by 80 
SERPINA1 gene mutations. Homozygous Z AATD mutation is the most clinically relevant 81 
among Caucasians (prevalence is about 1:2000-1:5000) that is characterized by low plasma 82 
levels of AAT protein (10-15% compared to the wild type, MM AAT, 1.3-2 g/L) and the 83 
presence of intracellular and circulating Z-AAT polymers
13
. The liver is the major producer of 84 
AAT, therefore the accumulation of Z-AAT polymers in hepatocytes is a marker for 85 
diagnosing AATD
14
.  The intracellular Z-AAT polymers have also been identified in other 86 
AAT expressing cells like monocytes and macrophages
15
. The accumulation of polymers is 87 
harmful for AAT-producing cells, whereas the circulating Z-AAT polymers are not able to 88 
execute the tasks of AAT protein, a major inhibitor of serine proteases having a strong 89 
immunomodulatory potential. Based on the facts that: i) circulating Z-AAT polymers 90 
contribute to the risk of developing pathologies
16,17
, ii) pathogenic oligomeric proteins affect 91 
CX3CR1 expression
12
 and iii) CX3CR1/CX3CL1 axis plays a significant role in immunity
18
, 92 
we aimed to investigate CX3CR1 expression in PBMCs of ZZ AATD individuals. For this, in 93 
collaboration with German Alpha1 Patient Association and Aachen University, was prepared 94 
RNA from freshly isolated PBMCs of 41 clinically stable ZZ AATD volunteers 95 
independently of their clinical diagnosis or treatment with intravenous AAT, a specific 96 
augmentation therapy
19
. For comparison, PBMCs isolated from healthy volunteers having 97 
normal plasma AAT levels were used. Additionally, a limited amount of RNA sample was 98 
available from PBMCs isolated from a cohort of 12 ZZ AATD emphysema patients at Leiden 99 
University Medical Center, The Netherlands (Figure 1–figure supplement 1).  100 
Independent of individual’s age, clinical diagnosis (healthy, lung or liver disease) or 101 
augmentation therapy, the CX3CR1 mRNA expression turned to be much lower in ZZ AATD 102 
PBMCs than in PBMCs from non-AATD controls [median (range): 4.1 (2.7-5.5) vs 18.5 (13-103 
26.6), p < 0.001] (Figure 1A). A previous study has shown that CX3CR1
-/- 
mice have 104 
significantly higher plasma levels of CX3CL1 than wild-type mice
20
. A diminished 105 
expression of CX3CR1 might be related to increased levels of soluble CX3CL1, an exclusive 106 
ligand for CX3CR1
1
. However, the concentration of plasma CX3CL1 was low, and did not 107 
differ between ZZ AATD and non-AATD individuals (Figure 1B), and did not correlate with 108 
CX3CR1 mRNA in PBMCs. The expression and release of CX3CL1 is generally low in the 109 
absence of inflammatory insults
21
 showing that at the time point of blood donation all 110 
volunteers were under stable clinical condition.   111 
Although CX3CR1 is preferentially expressed on monocytes, other cells also express this 112 
receptor
22
. Previous reports indicated that exogenous IL-15 is a negative regulator of 113 




. However, plasma levels of IL-15 were 114 
lower in ZZ AATD than in non-AATD [pg/ml, median (range): 6.6 (5.9-6.9), n = 23 vs 7.63 115 
(6.63-8.1), n = 21, p = 0.001], excluding a possible link between IL-15 and CX3CR1 mRNA.   116 
Because ZZ AATD individuals, differently from non-AATD, have about 90% lower blood 117 
concentration of Z-AAT protein, which may influence cellular microenvironment
25
, a 118 
relationship between CX3CR1 and Z-AAT plasma levels cannot be excluded. However, no 119 
correlation was found between CX3CR1 mRNA in PBMCs and plasma levels of Z-AAT 120 
measured by nephelometry (data not shown). Next, plasma Z-AAT polymers were measured, 121 
as the biomarkers of all carriers of the Z allele
13,26
. As anticipated, only minor amounts of 122 
polymers were detected in plasma of non-AATD individuals while plasma of ZZ AATD 123 
contained high amounts of polymers [µg/ml, mean (SD): 4.1 (6), n = 18 vs 1399.8 (750), n = 124 
20, respectively]. Since most of the ZZ AATD individuals received intravenous augmentation 125 
therapy with plasma purified AAT protein, ZZ AATD individuals were segregated into 126 
subgroups who receive or not receive therapy. There were no significant differences in Z-127 
AAT polymer levels between the subgroups: [µg/ml, median (range): non-augmented 1506.6 128 
(854-1781), n = 17 vs augmented 1348.5 (779.5-1529), n = 23, respectively]. A previous 129 
study used a sandwich ELISA based on 2C1 antibody and found that circulating Z-AAT 130 
polymers range between 8.2-230.2 μg/ml in ZZ AATD
13
 whereas much higher circulating 131 
levels of Z-AAT polymers were detected by using the single monoclonal antibody (LG96)- 132 
based ELISA. These discrepancies can be due to the differences between antibody 133 
specificities. For example, 2C1 showed high affinity for polymers formed by heating M- or Z-134 
AAT at 60°C
27
 while LG96 antibody recognizes naturally occurring/native Z-AAT polymers 135 
without requiring sample heating. To answer, why some individuals have higher plasma 136 
levels of Z-AAT polymers than monomers (measured by nephelometry) is of great 137 
importance for the further studies.  138 
Most interestingly, in ZZ-AATD individuals was found a trend towards an inverse 139 
relationship between CX3CR1 mRNA in PBMCS and plasma Z-AAT polymers (r
2 
= -0.31, n 140 
= 38, p = 0.055) (Figure 1C). This latter finding prompted more extensive investigation 141 
whether Z-AAT polymers affect CX3CR1 expression when added to healthy donor PBMCs 142 
for 18 h, ex vivo. Lipopolysaccharide (LPS, from Escherichia coli, 1 µg/mL) was included as 143 
a known reducer of CX3CR1 expression
28,29
. Indeed, polymeric Z-AAT in a concentration-144 
dependent manner lowered CX3CR1 mRNA (Figure 2–figure supplement 2) whereas 145 
repeated experiments using Z-AAT at a constant concentration of 0.5 mg/mL reduced 146 
CX3CR1 mRNA more than twice as compared to non-treated controls (Figure 2A). In 147 
accordance, LPS and polymer containing Z-AAT preparation significantly decreased surface 148 
expression of CX3CR1, specifically in CD14
+
 monocytes and NK cells (Figure 3).  149 
By contrast, cellular levels of CX3CR1 protein increased in PBMCs treated with Z-AAT 150 
polymers or LPS (used as a positive control) as compared to non-treated controls (Figure 2B). 151 
The CX3CR1 protein was present in detergent resistant lipid raft fraction of PBMCs treated 152 
with Z-AAT (Figure 2–figure supplement 3A). Total cell lysates and lipid raft fractions 153 
from Z-AAT-treated PBMCs, in contrast to those prepared from M-AAT-treated or non-154 
treated PBMCs, contained high amounts of AAT polymers (Figure 2C, figure 2-figure 155 
supplement 3B). The laser scanning confocal microscopy of double-labelled specimens 156 
showed a co-localization of Z-AAT polymers with CX3CR1 protein (Figure 2D). 157 
Furthermore, 3D reconstruction of cross-sections visualised larger Z-AAT aggregates 158 
surrounded by cellular extensions in a cap-like formation, suggesting that cells may react 159 
differently depending on the size of Z-AAT polymers (Figure 2E). It cannot be excluded, that 160 
Z-AAT polymers, similar like polymers of Tau protein, interact with CX3CR1 and get 161 
internalized
30
. This may determine the fate of CX3CR1 mRNA expression, i.e. sequestered 162 
intracellularly and not returning to the cell surface, CX3CR1 protein may induce signalling 163 
pathways lowering CX3CR1 expression. To achieve a definitive answer how Z-AAT or other 164 
types of protein polymers regulate CX3CR1 levels detailed mechanistic studies are required. 165 




Under the same experimental conditions, monomeric M-AAT had no effect on CX3CR1 168 
mRNA [expression relative to housekeeping gene HPRT1, mean (SD): 24.9 (2.9) controls, n 169 
= 5 vs 23.7 (1.3), n = 5, NS], and protein levels (Figure 2B). Likewise, monomeric Z-AAT 170 
protein does not affect CX3CR1 mRNA and protein levels, and heat-induced polymers of M-171 
AAT showed no effect on CX3CR1 expression as well (Figure 2-figure supplement 4). 172 
Probably, specific conformational properties and/or molecular sizes of Z-AAT polymers are 173 
required for their interaction with CX3CR1. For example, cell surfaces express CX3CL1 as a 174 
constitutive oligomer (three to seven molecules), which is essential for efficient interaction 175 
with CX3CR1
32,33
. Numerous chemokines tend to self-associate that determines their 176 
activity
34
, and therefore certain Z-AAT polymers may resemble chemokine structures 177 
competing for the same receptor(s). In some experimental models, Z-AAT polymers 178 
expressed strong chemotactic properties
16,35
. When chemokine receptors are engaged in 179 
chemotaxis, they can be removed from the cell surface by the ligand-receptor 180 
internalisation
36
, which might explain a decrease of CX3CR1 in ZZ PBMCs.  Interestingly, 181 
the soluble form of CX3CL1, even when used at a high concentration of 500 ng/ml, does not 182 
antagonize Z-AAT polymer effects on CX3CR1 mRNA and protein levels, and by itself 183 
showed no effect on CX3CR1 mRNA or protein levels (Figure 2-figure supplement 5), 184 
although some studies reported that CX3CL1 reduces CX3CR1 expression
28,37
. In solution 185 
CX3CL1 remains monomeric, even at high concentrations
32,38
 whereas, as mentioned above, 186 
membrane bound CX3CL1 occurs as oligomer. These two forms of the CX3CL1 perform 187 
differential roles
39
, and therefore it cannot be excluded that oligomeric, but not a soluble, form 188 
of CX3CL1 would compete with Z-AAT for CX3CR1 interaction in vivo.  189 
The CX3CR1 helps to define the major subsets of human monocytes because classical 190 
monocytes express much lower levels of CX3CR1 than non-classical monocytes
40
. After in 191 
vitro challenge with LPS for longer periods (like for 18 h), human monocytes are known to 192 
increase in the mRNA and membrane expression of CD14, a receptor for LPS
41
. The 193 
enhancement of CD14 expression after treatment of PBMCs with Z-AAT strikingly 194 
resembled LPS (Figure 4 and Figure 4–figure supplement 1). This raised a suspicion that Z-195 
AAT preparations might contain endotoxin. According to the Limulus Amebocyte Lysate 196 
Test (LAL), endotoxin levels of Z-AAT preparations were below detection limit (0.01 197 
EU/ml). Moreover, LPS significantly induced expression of TNFα, IL-6 and IL-1β while 198 
polymer containing Z-AAT preparations had no effect (Figure 4–figure supplement 2). 199 
Beside, LPS but not Z-AAT significantly increased release of cytokines [IL-1β, pg/ml, 200 
median (range): LPS 1342.9 (1008-1834) vs Z-AAT 3.2 (2.5-5.9) vs controls 2.5 (2.1-3.7), n 201 
= 4 independent experiments; TNFα, ng/ml, mean (SD): LPS 19.5 (2.5) vs Z-AAT vs 202 
controls, undetectable, n = 4 and IL-6, ng/ml, median (range): LPS 15903.5 (14626-17262) vs 203 
Z-AAT 5.4 (2.9-6.1) vs control (1.7 (1.0-2.3), n = 4]. Therefore, the effect of Z-AAT 204 
preparations on CD14 is valid and unrelated to a potential LPS-contamination. Although both 205 
Z-AAT polymers and LPS induce CD14 expression and similarly affect CX3CR1 expression 206 
and protein levels, data imply that Z-AAT polymers and LPS do not share the same signalling 207 
mechanisms.   208 
As a side note, it has been reported that CD14
++
 monocytes have the lowest expression of 209 
CX3CR1
42
. Low and high surface CX3CR1 levels are suggested to delineate two functional 210 
subsets of murine blood monocytes: “inflammatory” and “resident monocytes,”
43
. This 211 








 monocytes 212 
resemble “inflammatory” and “resident” monocytes. Previous study demonstrated that 213 
peripheral blood monocytes of clinically healthy young adults (30-year old) with ZZ AATD 214 
have significantly higher mRNA and surface expression of CD14 as compared to age matched 215 
MM subjects
44
. Authors thought that the higher CD14 expression reflects early pathological 216 
processes whereas according to the current findings this phenomenon seems to relate with the 217 
circulating Z-AAT polymers.  218 
During steady state, non-classical monocytes expressing CX3CR1 patrol healthy tissues 219 
through crawling on the resting endothelium but these monocytes are required for a rapid 220 
tissue invasion at the site of infection or inflammation
45,46
.  Previous work evidenced that the 221 
non-classical subset of monocytes, characterized by high expression of CX3CR1, is almost 222 
absent in ZZ AATD emphysema patients
47
. Moreover, plasma levels of AAT polymers were 223 
found to correlate with the levels of endothelium-related markers like sE-selectin and sICAM-224 
1
48
. Beyond, in a small cohort of ZZ AATD emphysema patients was found a strong inverse 225 
association between lung function, based on percentage (%) predicted transfer factor for 226 
carbon monoxide (TLCO%pred) and forced expiratory volume in 1 second (FEV1%pred), 227 
and plasma levels of Z-AAT polymers: [TLCO%pred (r
2
=-0.75, n=9, p=0.02) and 228 
FEV1%pred (r
2
=-0.82, n=9, p=0.006)]. Thus, higher levels of Z-AAT polymers and lower 229 
numbers of CX3CR1-positive cells may favour the development of lung injury and disease. A 230 





.  232 
To date, many functional aspects of the CX3CR1-CX3CL1 axis have been suggested, 233 
including the adhesion of immune cells to vascular endothelial cells, chemotaxis, the crawling 234 
of the monocytes that patrol on vascular endothelial cells, the retention of monocytes of the 235 
inflamed endothelium to recruit inflammatory cells, and the survival of the macrophage. 236 
Considering the above, these different aspects of interactions between PBMCs and Z-AAT or 237 
other polymers occurring due to genetic or post-translational protein modifications require 238 
further investigations in dedicated clinical and experimental studies.  239 
Material and methods 240 
































































































CSL Behring Respreeza  
Other LPS Sigma-Aldrich L2880 Escherichia 
coli O55:B5 
commercial 









assay or kit 































































































































Study approval 242 
The study cohort consists of 41 clinically stable ZZ AATD volunteers collected in 243 
collaboration with German Alpha1 Patient Association and Aachen University independently 244 
on their clinical diagnosis or treatment with intravenous AAT and 21 non-AATD healthy 245 
controls. The institutional review board of Aachen University (EK 173/15) provided ethical 246 
approval for individuals recruited in Germany. For Z-AAT polymer determination, we added 247 
12 ZZ AATD emphysema patients recruited at Leiden University Medical Center. In addition, 248 
9 ZZ AATD emphysema patients (4 males and 5 female) were enrolled with mean (SD): age 249 
51 (6.6) years, forced expiratory volume in 1 second percent predicted [FEV1%pred, 66.3 250 
(28)] and transfer factor of the lung for carbon monoxide percent predicted (TLCO%pred, 64 251 
(29)]. The plasma levels of Z-AAT polymers in these cases were median (range) 714.2 252 
(412.9-2270.4) µg/mL). Leiden University Medical Center provided ethical approval (project 253 
P00.083 and P01.101) for the additional study groups. For all individuals detailed medical 254 
records data were anonymized. All participants issued a written informed consent according 255 
to the ethical guidelines of the Helsinki Declaration (Hong Kong Amendment) as well as 256 
Good Clinical Practice (European guidelines).  257 
Isolation of PBMCs  258 
Total PBMCs were isolated from freshly obtained peripheral blood (within 6 hours) using 259 
Lymphosep (C-C-Pro, Oberdorla, Germany) discontinuous gradient centrifugation according 260 
to the manufacturer's instructions as described previously
50
. Thereafter, cells were lysed with 261 
RLT buffer for RNA analysis or suspended in RPMI-1640 medium (Gibco, Thermofisher 262 
Scientific, Waltham, MA, USA) and plated into non-adherent 12-well plates (Greiner Bio-263 
one, Kremsmünster, Austria) for the further analyses. 264 
RT-PCR analysis 265 
Isolation of total RNA, synthesis of cDNA and mRNA analysis using Taqman gene 266 
expression assays (Thermofisher Scientific, Waltham, MA, USA, Table 1) were performed as 267 
described previously
50
. RT PCR was carried out in duplicates. RNA quality was checked on 268 
agarose gels. 269 








AAT polymer ELISA 278 
The AAT polymer ELISA using the monoclonal antibody LG96 (deposited under access No 279 
DSM ACC3092 at German Collection of Microorganisms and Cell Cultures) was developed 280 
by Candor Biosciences. Normal M-AAT was used for a negative control. Recovery ratio, 281 







signal-to noise ratio, calibration curve, sample stability under different storage conditions 282 
were tested and all tests passed. A cross reactivity with M-AAT was not reported in any of the 283 
tests. Nunc MaxiSorp flat-bottom 96-well plates (Thermofisher, Waltham, MA, USA) were 284 
coated overnight at 2-8 °C with monoclonal antibody LG96, at 1 µg/ml in coating buffer pH 285 
7.4 (Candor Biosciences, Wangen, Germany). After a 2 h blocking step, the plasma samples 286 
were applied in the previously determined dilutions made in LowCross-Buffer (Candor 287 
Biosciences), which also served as a blank. Incubation was performed for 2 h at RT. For 288 
detection, the captured antigen was incubated with antibody (LG96)-horseradish peroxidase 289 
(HRP) conjugate (1:2000) for 2 h. The conjugate was prepared in advance with the HRP 290 
Conjugation Kit Lightning-Link (Abcam, Cambridge, UK) according to the manufacturer's 291 
instructions. For signal development SeramunBlau fast2 microwell peroxidase substrate 292 
(Seramun, Heidesee, Germany) was used. The incubation was performed at room temperature 293 
for 12 minutes in the dark and the reaction was stopped with 2 M H2SO4. Plates were 294 
analyzed at 450 nm by microplate reader (Dynex Chantilly, VA, USA) equipped with Dynex 295 
Revelation 4.21 software. Measurements were carried out in triplicates. 296 
Preparation of AAT proteins 297 
Plasma M- and Z-AAT was isolated by affinity chromatography using the AAT specific 298 
Alpha-1 Antitrypsin Select matrix (GE Healthcare Life Sciences, Cytiva, Sheffield, UK) 299 
according to the manufacturer's recommendations. For Z-AAT preparation plasma from 300 
volunteers not receiving AAT augmentation therapy was pooled. To change the buffer in the 301 
M- and Z-AAT protein pools to Hank’s balanced salt solution (HBSS, Merck, Darmstadt, 302 
Germany) Vivaspin centrifugal concentrators with 10,000 MWCO (Vivaproducts, Littleton, 303 
MA, USA) were used. Plasma purified human AAT (99% purity, Respreeza, Zemaira, CSL 304 
Behring, Marburg, Germany) was changed to HBSS by the same method. Protein 305 
concentrations were determined using Pierce BCA Protein Assay Kit (Thermofisher, 306 
Waltham, MA, USA). The quality of the M- and Z-AAT preparations was confirmed on 307 
Coomassie gels (10% SDS PAGE, Figure 2–figure supplement 1A) and by analyzing 308 
endotoxin levels with Pierce Chromogenic Endotoxin Quant Kit according to the 309 
manufacturer’s guidelines (Thermofisher, Waltham, MA, USA) using TECAN Infinite M200 310 
PRO (Männedorf, Switzerland). In both, M and Z-AAT preparations, endotoxin levels were 311 
below the detection limit (Assay sensitivity: 0.01-0.1 EU/ml).  312 
Preparation of Z-AAT monomers 313 
Z-AAT was isolated by affinity chromatography using AAT specific Alpha-1 Antitrypsin 314 
Select matrix as described above. After the isolation Z-AAT, protein was diluted with sterile 315 
0.9% NaCl (Fresenius Kabi, Bad Homburg, Germany), and Vivaspin-20, 100 kDa centrifugal 316 
column units (Sartorius, Göttingen, Germany) were used to separate Z-AAT monomers from 317 
polymers. Protein concentrations were determined using the Pierce BCA Protein Assay Kit 318 
(Thermofisher Scientific, Carlsbad, CA, USA) according to manufacturer’s instructions. The 319 
Z-AAT protein monomers were confirmed by using 7.5% SDS-PAGE without sample heating 320 
and without β-mercaptoethanol (Figure 2-figure supplement 1B). 321 
In vitro experiments with PBMCs from healthy donors 322 
PBMCs (5 × 10
6 
cells/ml) were incubated for 18 h at 37 °C, 5% CO2 either alone, or with Z- 323 
or M-AAT proteins, or lipopolysaccharide (LPS, 1 µg/mL, Escherichia coli O55:B5, Sigma-324 
Aldrich, Merck, St. Louis, Missouri, USA). In some experiments, a recombinant CX3CL1 325 
protein (R&D Systems, Bio-Techne, Minnesota, USA) was used. Protein was reconstituted at 326 
a concentration of 25 µg/ml in sterile PBS containing 0.1% BSA (Sigma-Aldrich) and added 327 
to PBMCs at various concentrations up to 500 ng/ml either alone or together with Z-AAT (0.5 328 
mg/ml) for 18 h. Afterwards, cells were used for RNA isolation, flow cytometry or Western 329 
blot analysis. For Western blot, PBMCs were lysed in RIPA buffer (Sigma-Aldrich), 330 
supplemented with protease inhibitor cocktail (Sigma-Aldrich). For some Western blot 331 
experiments, we extracted detergent resistant lipid raft associated proteins from insoluble cell 332 
fractions using UltraRIPA kit according to the supplier’s instructions (BioDynamics 333 
Laboratory, Tokio, Japan). 334 
Western blot 335 
Equal amounts of lysed proteins were separated by 7.5% or 10% SDS-polyacrylamide gels 336 
(under reducing conditions for CX3CR1 and non-reducing for total AAT or AAT polymer 337 
analysis) prior to transfer onto polyvinylidene difluoride (PVDF) membranes (Merck-338 
Millipore, Burlington, MA, USA). Membranes were blocked for 1 h with 5% low fat milk 339 
(Carl Roth, Karlsruhe, Germany) followed by overnight incubation at 4 °C with specific 340 
primary antibodies: polyclonal rabbit anti-human AAT (1:800) (DAKO A/S, Glostrup, 341 
Denmark), mouse monoclonal anti-AAT polymer antibody (clone 2C1, 1:500, Hycult 342 
Biotech, Uden, The Netherlands), rabbit polyclonal anti-CX3CR1 (1:500, Abcam, Cambridge, 343 
UK), or HRP-conjugated monoclonal anti β-actin antibody (1:20,000, Sigma-Aldrich, Merck, 344 
St. Louis, Missouri, USA) for a loading control. The immune complexes were visualized with 345 
anti-rabbit or anti-mouse HPR-conjugated secondary antibodies (DAKO A/S) and enhanced 346 
by Clarity Western ECL Substrate (BioRad, Hercules, CA, USA). Images were acquired by 347 
using Chemidoc Touch imaging system (BioRad) under optimal exposure conditions and 348 
processed using Image Lab version 5.2.1. software (Bio-Rad). For quantification, the signal 349 
intensity of the CX3CR1 protein band in each lane was divided by the corresponding β-actin 350 
band intensity (normalization factor or loading control). Afterwards, the normalized signal of 351 
each lane was divided by the normalized target signal observed in the control sample to get 352 
the abundance of the CX3CR1 protein as a fold change relative to the control.  353 
ELISA 354 
Plasma samples from 22 ZZ-AATD and 21 non-AATD controls were analyzed for CX3CL1/ 355 
Fractalkine using Duoset kit (R&D systems, Minneapolis, MN, USA, assay sensitivity 0.072 356 
ng/ml, detection range 0.2-10 ng/ml). Cell free culture supernatants were analyzed directly or 357 
stored at -80˚C. ELISA Duoset kits for TNF-α (assay detection range 15.6-1000 pg/ml), IL-358 
1β/IL-1F2 (assay detection range 3.91-250 pg/ml), and IL-6 (assay detection range 9.38-600 359 
pg/ml) were purchased from R&D Systems (Minneapolis, MN, USA) and were used 360 
according to the manufacturer’s instructions. Plates were measured on Infinite M200 361 
microplate reader (Tecan, Männedorf, Switzerland). Measurements were carried out in 362 
duplicates. 363 
Flow cytometry analysis  364 
PBMCs (2 × 10
6 
cells per condition) were incubated with LPS (1 µg/ml), M-AAT (1 mg/ml), 365 
or Z-AAT (0.5 mg/ml) for 18 h. Staining was performed with phycoerythrin (PE)-conjugated 366 
mouse monoclonal anti-CX3CR1 antibody (clone 2A9-1 Invitrogen, Thermofisher Scientific, 367 
Carlsbad, CA, USA), fluorescein (FITC)-conjugated mouse monoclonal anti-CD14 antibody 368 
(clone TuK4, Life technologies, Thermofisher Scientific, Carlsbad, CA, USA), 369 
allophycocyanin (APC)-conjugated mouse monoclonal anti-CD16 antibody (clone 3G8, 370 
Immunotools, Friesoythe, Germany), or BV-480 conjugated anti-CD56 mouse monoclonal 371 
antibody (Clone  NCAM16.2, BD Biosiences, San Jose, CA, USA) alone or in combinations. 372 
Dead cells were excluded by a staining with 7-amino-actinomycin D (7-AAD). Samples were 373 
measured on a BD FACSAria Fusion machine and analyzed with FlowJo v10 (Becton, 374 
Dickinson and Company, Franklin Lakes, NJ, USA). The gating strategy is shown in Figure 375 
3–figure supplement 1.  376 
Immunofluorescence Confocal Laser Microscopy 377 
Human total PBMCs (2 ×10
6
) were plated onto glass coverslips and incubated alone or with 378 
Z-AAT polymers (0.5 mg/ml) in RPMI medium for 18 h at 37°C and 5% CO2. Cells were 379 
then washed with PBS, fixed with 3% paraformaldehyde in PBS for 20 min and continued 380 
with or without permeabilization with 0.5% Triton X-100 in PBS for 5 min at RT. For 381 
immunolabeling, cells were co-incubated with primary antibodies against human CX3CR1 382 
(rabbit polyclonal IgG (1:500), Abcam, Cambridge, UK) and anti-AAT polymer antibody, 383 
D11 (1:5000, mouse monoclonal) for 1 h, at RT. After washing, the cells were incubated with 384 
corresponding secondary antibodies (1:1000) conjugated to AlexaFluor-488 (goat anti-rabbit) 385 
or AlexaFlour-594 (goat anti-mouse) both from Thermo Fisher Scientific, Rockford, USA. 386 
After final wash, the cells were mounted on microscope slides using ProLong Gold Antifade 387 
Mountant with DAPI (Thermo Fisher Scientific, Carlsbad, CA, USA). Images were acquired 388 
using confocal laser microscope FluoView 1000 (Olympus, Shinjuku, Japan) equipped with a 389 
60x oil immersion objective and differential interference contrast (DIC) in sequential mode. 390 
Confocal z-stacks were collected with a 0.25 µm increment. 391 
Statistics 392 
Data were analyzed and visualized by using Sigma Plot 14.0. One-tailed Student’s t-test was 393 
applied to compare two sample means on one variable. When more than two groups were 394 
involved in the comparison, one-way ANOVA was used. Data were presented as mean (SD). 395 
If normality test failed, the nonparametric Kruskal-Wallis one-way analysis or Mann-Whitney 396 
Rank Sum test was performed, and data were presented as median (range). For correlation 397 
analysis the Pearson’s linear correlation method was used to measure the correlation for a 398 
given pair. A p-value of less than 0.05 was considered significant.  399 
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  567 
Figures and legends  568 
 569 
Figure 1.  A CX3CR1 gene expression in PBMCs isolated from AATD subjects and non-570 
AATD controls. CX3CR1 gene expression relative to HPRT1 housekeeping gene was 571 
determined by real-time PCR using Taqman gene expression assays. Measurements were 572 
carried out in duplicates. Data are presented as median (IQR) in boxplots, lines represent 573 
medians. Outliers are defined as data points located outside the whiskers. p-value was 574 
calculated by the difference between the Mann-Whitney U test. B Plasma levels of CX3CL1 575 
in AATD (plasma available for n = 38 AATD) and non-AATD individuals measured by 576 
ELISA. Measurements were carried out in triplicates. Data are presented as median (IQR) in 577 
boxplots with whiskers. Outliers are defined as data points located outside the whiskers. C 578 
Negative correlation of CX3CR1 mRNA in PBMCs and plasma Z-AAT polymer levels from 579 
ZZ-AATD individuals from graph (B). Person’s correlation test, r
2
 = -0.313, p = 0.055, n = 580 
38. 581 
The online version of this article includes the following source data and figure supplement(s) 582 
for figure 1: 583 
Figure 1—Source data 1. Source files, containing original data for Figure 1 A and B, to 584 
document CX3CR1 expression (A), and plasma levels of CX3CR1 in AATD and non-AATD 585 
individuals (B). 586 
Figure 1—Figure supplement 1.  Schematic presentation of the study design. 587 
 588 
 589 
Figure 2. Effects of Z-AAT and M-AAT on CX3CR1 mRNA and protein expression. A 590 
CX3CR1 gene expression relative to HPRT1 housekeeping gene was determined by real-time 591 
PCR using Taqman gene expression assays. PBMCs were incubated for 18 h with plasma-592 
derived Z-AAT, LPS or M-AAT in the concentrations as indicated, or with RPMI medium 593 
alone (control). The data from n = 6 independent experiments are presented as median (IQR) 594 
in box and whisker plot format; lines represent medians in each box. Measurements were 595 
carried out in duplicates. p was calculated by nonparametric Kruskal-Wallis test). B 596 
Representative uncut Western blot (n = 3 independent experiments) of CX3CR1 in RIPA 597 
lysates prepared from PBMCs incubated for 18 h alone or with LPS (1 µg/ml), M-AAT (1 598 
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separated by SDS-PAGE under reducing conditions. Relative intensities were calculated for 600 
each band using the ratio relative to β-actin, as a loading control, and then normalized by the 601 
experimental control. C For analysis of cellular AAT the same lysates were separated under 602 
non-reducing conditions. Western blots were probed with polyclonal rabbit anti human AAT 603 
recognizing monomeric, polymeric, or truncated forms of AAT. One representative blot from 604 
n = 3 independent experiments is shown. β-actin was used for a loading control. D and E. Co-605 
distribution of Z-AAT polymers with CX3CR1 in human total PBMCs incubated with 0.5 606 
mg/ml Z-AAT polymers for 18 h. D Immunofluorescence microscopy revealed co-607 
localization of Z-AAT polymers (red) with CX3CR1-positive structures (green). Arrows 608 
point areas of co-localization. Scale bar, 10 µm. E Confocal microscopy 3D-stack with 609 
orthogonal reconstruction shows an aggregate of Z-AAT polymers (red) surrounded by 610 
CX3CR1-positive (green) cellular extensions forming a cap-like structure (arrowhead). Scale 611 
bar, 5 µm. The images with indicated channels merged and the corresponding DIC image are 612 
presented. DAPI was used for nuclei staining (blue). 613 
The online version of this article includes the following source data for figure 2: 614 
Figure 2—Source data 1. Source file, containing original data for Figure 2A, to document 615 
CX3CR1 reduced expression in PBMCs treated with Z-AAT or LPS (A).  616 
Figure 2—Figure supplement 1. Quality control of isolated M- and Z-AAT proteins by 617 
SDS-PAGE.  618 
Figure 2—Figure supplement 2. Z-AAT in a concentration-dependent manner reduces 619 
CX3CR1 mRNA expression in PBMCs isolated from healthy donors. 620 
Figure 2—Figure supplement 3. Z-AAT induces association of CX3CR1 with lipid rafts. 621 
Figure 2—Figure supplement 4. CX3CR1 transcript and protein expressions in presence of 622 
Z-AAT monomer, Z-AAT polymer, native M-AAT and M-AAT polymer. 623 
Figure 2—Figure supplement 5. Effect of CX3CL1 alone or in combination with Z-AAT on 624 
CX3CR1 transcript and protein expression. 625 
  626 
 627 
Figure 3. Flow cytometric analysis of CX3CR1 surface expression in PBMCs after 628 
incubation with RPMI alone (control), Z-AAT or LPS in the concentrations as indicated for 629 





) (B). Histograms show representative results and bars represent mean (SD) of 631 
n = 4 independent biological repeats each measured one time. After incubation with Z-AAT 632 
or LPS monocytes and NK cells show significantly reduced CX3CR1 surface expression in 633 
comparison to untreated control cells. p-values were calculated by one-way ANOVA.  634 
The online version of this article includes the following source data and figure supplement(s) 635 
for figure 3: 636 
Figure 3—Source data 1. Source files, containing original data for Figure 3A,B to document 637 
reduced CX3CR1 surface expression monocytes (A) and NK cells (B) after treatment with Z-638 
AAT or LPS (A).  639 
Figure 3—Figure supplement 1. Gating strategy: Sequential gating to identify monocytes 640 
and NK cells from total PBMCs. 641 
 642 
 643 
Figure 4. Z-AAT and LPS induce CD14 expression. A Z-AAT increases CD14 gene 644 
expression. PBMCs were incubated for 18 h with 0.5 mg/ml Z-AAT or RPMI medium alone 645 
(control). CD14 mRNA expression relative to HPRT1 was determined by real-time PCR 646 
using Taqman gene expression assays. Measurements were carried out in duplicates. Data are 647 
represented as median (IQR) in boxplots, lines represent medians of n = 14 independent 648 
biological repeats. Outliers are defined as data points located outside the whiskers. p-values 649 
were calculated using nonparametric Kruskal-Wallis test.  650 
B Z-AAT increases monocyte CD14 surface expression. PBMCs were cultured with RPMI 651 
(control), Z-AAT or LPS for 18 h. CD14 mean fluorescence intensities of monocytic cells 652 
were determined by flow cytometry. Histograms show representative results and bars 653 
represent mean (SD) of n = 4 independent biological repeats each measured one time. p-654 
values were calculated from ANOVA. 655 
The online version of this article includes the following source data and figure supplement(s) 656 
for figure 4: 657 
Figure 4—Source data 1. Source files, containing original data for Figure 6 A,B to document 658 
CD14 gene expression in PBMCs (A) and CD14 surface expression in monocytes (B).  659 
Figure 4—Figure supplement 1. Inverse changes in CD14 and CX3CR1 gene expression in 660 
PBMCs treated with rising concentrations of Z-AAT. 661 
Figure 4—Figure supplement 2. Z-AAT doesn’t induce cytokine expression. PBMCs were 662 
treated with Z-AAT or LPS (used as a positive control) for 18 h. 663 
  664 
Legends for supplementary figures 665 
Figure 1–figure supplement 1.  Schematic presentation of the study design. The German 666 
cohort comprises 41 ZZ-Alpha1 Antitrypsin deficient (AATD) volunteers irrespective of 667 
clinical status and medications. For control, we collected blood from 21 non-AATD 668 
volunteers with normal AAT blood levels. We prepared PBMCs for further gene expression 669 
analysis by real-time PCR and plasma for determination of Z-AAT polymers by 670 
nephelometry. The Leiden cohort consisting of 12 ZZ-AATD emphysema patients was used 671 
for gene expression analysis.  672 
Figure 2–figure supplement 1. Quality control of isolated M- and Z-AAT proteins by SDS-673 
PAGE. A. Plasma M- and Z-AAT was purified by affinity chromatography with AAT specific 674 
Alpha1 Antitrypsin Select matrix. Proteins were run on a 10 % SDS-PAGE gel and stained 675 
with Coomassie Blue G250. AAT (Respreeza) was added as a positive control. Gels were run 676 
for each protein preparations. One representative gel is shown. B.  Z-AAT polymers were 677 
purified by affinity chromatography with AAT specific Alpha1 Antitrypsin Select matrix and 678 
monomeric Z-AAT was separated by using vivaspin-20, 100 kDa centrifugal column units. Z-679 
polymers, Z-monomers and native AAT (as control) were run on a 10 % SDS-PAGE gel 680 
without sample heating and without β-mercaptoethanol, and stained with Coomassie Blue 681 
G250. Representative gel is shown. 682 
Figure 2–figure supplement 2. Z-AAT in a concentration-dependent manner reduces 683 
CX3CR1 mRNA expression in PBMCs isolated from healthy donors. PBMCs were incubated 684 
for 18 h with plasma-derived Z-AAT in the concentrations as indicated. CX3CR1 gene 685 
expression relative to HPRT1 housekeeping gene was determined by real-time PCR using 686 
Taqman gene expression assays. Curves show results from two independent experiments. 687 
Each point represents mean of two repeats. 688 
Figure 2–figure supplement 3. Z-AAT induces association of CX3CR1 with lipid rafts. 689 
Lipid rafts were solubilized from membrane fractions with ULTRA RIPA kit. a For analysis 690 
of CX3CR1, equal amounts of protein were separated by SDS-PAGE under reducing 691 
conditions. One representative blot from n = 3 independent experiments is shown. b For 692 
analysis of lipid raft associated AAT polymers the same samples were separated under non-693 
reducing conditions. The Western blot was probed with monoclonal antibody (2C1) 694 
recognizing polymeric AAT. One representative blot from n = 3 independent experiments is 695 
shown. 696 
Figure 2–figure supplement 4. CX3CR1 transcript and protein expressions in the presence 697 
of Z-AAT monomer, Z-AAT polymer, native M-AAT and M-AAT polymer. A CX3CR1 698 
mRNA expression relative to HPRT1 was determined by real-time PCR using Taqman gene 699 
expression assays. PBMCs were incubated for 18 h in RPMI medium alone or with addition 700 
of Z-AAT monomer or Z-AAT polymer (each 0.5 mg/ml), or LPS (1µg/ml) or native M-AAT 701 
(0.5 mg/ml). Measurements were carried out in duplicates. Data are represented as bars from 702 
four independent experiments. B Levels of CX3CR1 lysates prepared in RIPA buffer from 703 
PBMCs incubated for 18 h with RPMI (control) and with Z-AAT monomer (0.5 mg/ml) or 704 
LPS (1µg/ml) (used as a positive control). For analysis of CX3CR1, equal amounts of protein 705 
were separated by 10% SDS-PAGE under reducing conditions followed by western blotting. 706 
Representative uncut Western blot (n = 2 independent experiments) is shown. β-actin was 707 
used for a loading control. C CX3CR1 mRNA expression relative to HPRT1 was determined 708 
by real-time PCR using Taqman gene expression assays. PBMCs were incubated for 18 h in 709 
RPMI medium alone or with different concentrations of heat-induced M-AAT polymers 710 
(60C, for 3h). Measurements were carried out in duplicates. Data are represented as curves 711 
from two independent donors. 712 
Figure 2–figure supplement 5. Effect of CX3CL1 alone or in combination with Z-AAT on 713 
CX3CR1 transcript and protein expression. PBMCs were incubated for 18 h with CX3CL1 714 
and Z-AAT polymers separately or in combination or with RPMI medium alone (control). A 715 
CX3CR1 gene expression relative to HPRT1 housekeeping gene was determined by real-time 716 
PCR using Taqman gene expression assays. The data from n = 8 independent experiments for 717 
control and 100 ng/ml CX3CL1 conditions and n = 4 for 500 ng/ml CX3CR1 conditions with 718 
or without Z-AAT are presented as mean (SEM). Measurements were carried out in 719 
duplicates. P values were calculated from one-way ANOVA test. B Levels of CX3CR1 in 720 
RIPA lysates prepared from PBMCs incubated for 18 h with RPMI (control) and with 721 
CX3CL1 (100 ng/ml) and Z-AAT (0.5 mg/ml) separately or in combination. For analysis of 722 
CX3CR1, equal amounts of protein were separated by SDS-PAGE under reducing conditions 723 
followed by western blotting. Representative uncut Western blot (n = 2 independent 724 
experiments) is shown. β-actin was used for a loading control. 725 
Figure 2-figure supplement 5-Source data 1. Source file, containing original data for Figure 726 
5A to document CX3CR1 gene expression in PBMC. 727 
Figure 3–figure supplement 1. Gating strategy: Sequential gating to identify monocytes and 728 
NK cells from total PBMCs. PBMCs were stained with CD14, CD16 and CD56 in the 729 
presence of 7-amino-actinomycin D (7-AAD). Dead cells were excluded by 7-AAD. From the 730 
single cells, CD14
+
 cells with a mid-level of granularity (SSC mid) were further gated for a 731 
mid-level FSC to identify monocytes. For the identification of NK cells, CD56
+
 cells with a 732 
low-level of granularity (SSC low) were further selected by CD16. The above plots are 733 
representative for four different donors. 734 
Figure 4–figure supplement 1. Inverse changes in CD14 and CX3CR1 mRNA expression in 735 
PBMCs treated with different concentrations of Z-AAT. PBMCs were incubated for 18 h with 736 
plasma-derived Z-AAT in the concentrations as indicated, or with RPMI medium alone 737 
(control). CX3CR1 and CD14 gene expression relative to HPRT1 housekeeping gene was 738 
determined by real-time PCR using Taqman gene expression assays. Curves represent two 739 
independent experiments. 740 
 741 
Figure 4–figure supplement 2. Z-AAT doesn’t induce cytokine expression. PBMCs were 742 
treated with Z-AAT or LPS (used as a positive control) for 18 h. IL1B (a), IL6 (b) and TNFA 743 
(c) mRNA expression relative to HPRT1 housekeeping gene was determined by real-time 744 
PCR using Taqman gene expression assays. Data presented as median (IQR) in box and 745 
whisker plots, lines represent medians, outliers are defined as data points located outside the 746 
whiskers. n = 4 independent experiments. p-values were calculated by Kruskal-Wallis one-747 
way analysis. 748 
Figure 4–figure supplement 2—Source data 1. Source files, containing original data for 749 
Figure 4-figure supplement 2 to document IL1B (A), IL6 (B) and TNFA (C) gene expression 750 
in PBMCs.  751 
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